Pharmacist-Led Daily Antimicrobial Density Reporting Cuts ICU Consumption

This single-center interrupted time series suggests that a unit-based clinical pharmacist delivering an individualized daily antimicrobial use density report can reduce ICU antimicrobial consumption and cost while shifting prescribing toward narrower agents.

antimicrobial stewardshipclinical pharmacistintensive care unitdefined daily dosescarbapenemstigecyclinefluoroquinolonesWHO AWaReinterrupted time seriesantimicrobial resistance Clinical Pharmacy Practice

Background Information

Unit-based pharmacists revolutionize ICU antimicrobial stewardship.

Antimicrobial resistance in ICUs poses a serious threat to patient safety, necessitating effective stewardship strategies. The intervention led to a significant reduction in antimicrobial use by 29.0 DDDs/100 patient-days and decreased costs by 8304 CNY per hospitalization. This UBCP-led model shows promise in enhancing antimicrobial stewardship but findings are limited to a single-center ICU. Unit-based clinical pharmacists can significantly improve antimicrobial use and costs in the ICU setting.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Huang T, Zhu D, Luo J, Zhang H, Qiu Y, Wen Y, Liu G, Wen H, Liu T

Citation: Huang T, Zhu D, Luo J, et al. Practice model of unit-based clinical pharmacists' individualized daily antimicrobial use density monitoring report on antimicrobial stewardship in intensive care unit of a tertiary hospital in Guangxi, China: an interrupted time series analysis. Antimicrobial resistance and infection control. 2026. doi:10.1186/s13756-026-01786-9

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →